AstraZeneca and Bristol Myers Squibb Explore Potential $400 Billion Merger
British pharmaceutical company AstraZeneca is reportedly in preliminary talks with US-based Bristol Myers Squibb about a potential merger valued at nearly $400 billion, which would create one of the world's largest pharmaceutical firms. The discussions, ongoing for several months, have not yet resulted in a formal agreement. AstraZeneca's shares fell following the news, while Bristol Myers Squibb's shares rose. The deal could face regulatory scrutiny in the US. Both companies declined to comment on the reports.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (58/100). Lens Score 43/100.
Outlets measured: mint, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–62/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 3 Aug, 03:21 am. Other outlets followed.